VistaGen Therapeutics Company Presentation

www.vistagen.com 16 Screening N=400 LSAS>70 Placebo Baseline Public Speaking Challenge N=300 SUDS>75 Placebo Public Speaking N=91 Open Label Safety SUDS<75 PH94B Public Speaking N=91 Follow-up and Open Label Safety Open Label Safety LSAS<70 PH94B North American Pivotal Phase 3 SAD Study: Public Speaking Visit 1 Visit 2 Visit 3 Visit 4